Sleep disturbances and their correlation with cardiovascular risk, obesity, and mood disorders in people with HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
medline:
6
4
2023
pubmed:
2
2
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
The relationship between sleep disorders (SDs), cardiovascular risk (CVR), and mood disorders (MDs) has been studied in detail in the general population, but far less in people with HIV (PWH). Cross-sectional analysis in single centre cohort of PWH. Sleep quality was assessed using by Epworth Sleepiness Scale (ESS), Insomnia Severity Index (ISI), Berlin Questionnaire (BQ), Pittsburgh Sleep Quality Index (PSQI); anxiety and depression were evaluated by the Generalized Anxiety Disorder-7 and Patient Health Questionnaire-9. Demographic, clinical and HIV-related data were collected, and Framingham and Data collection on Adverse effects of anti-HIV Drugs (DAD)-10 scores were computed in modelling associations with each SDs scale. Data were collected for 721 PWH on stable combination antiretroviral therapy (cART) (median age of 53 years, 71.8% males, 96% with undetectable HIV RNA, 50.3% on cART potentially affecting sleep, and 20.4% on hypno-inducing drugs), 76.9% had SDs 60.3, 31.3, 31.1, and 7.9% at PSQI, BQ, ISI, and ESS, respectively. Anxiety and depression were detected in 28.3 and 16.1% participants, respectively. BQ score was independently associated with high BMI ( P < 0.001), Framingham risk >10% ( P < 0.001), and both DAD-10R and -10F score >10% ( P < 0.001 and P = 0.031). PSQI and ISI scores were independently associated with depression and anxiety ( P < 0.001). No association between SDs and specific antiretroviral regimens, nor HIV-related parameters was detected. In our cohort of PWH on stable ART, despite the alarmingly higher prevalence, SDs were associated with the same determinants (cardiovascular risk factors and MDs) observed in the general population.
Sections du résumé
BACKGROUND
The relationship between sleep disorders (SDs), cardiovascular risk (CVR), and mood disorders (MDs) has been studied in detail in the general population, but far less in people with HIV (PWH).
METHODS
Cross-sectional analysis in single centre cohort of PWH. Sleep quality was assessed using by Epworth Sleepiness Scale (ESS), Insomnia Severity Index (ISI), Berlin Questionnaire (BQ), Pittsburgh Sleep Quality Index (PSQI); anxiety and depression were evaluated by the Generalized Anxiety Disorder-7 and Patient Health Questionnaire-9. Demographic, clinical and HIV-related data were collected, and Framingham and Data collection on Adverse effects of anti-HIV Drugs (DAD)-10 scores were computed in modelling associations with each SDs scale.
RESULTS
Data were collected for 721 PWH on stable combination antiretroviral therapy (cART) (median age of 53 years, 71.8% males, 96% with undetectable HIV RNA, 50.3% on cART potentially affecting sleep, and 20.4% on hypno-inducing drugs), 76.9% had SDs 60.3, 31.3, 31.1, and 7.9% at PSQI, BQ, ISI, and ESS, respectively. Anxiety and depression were detected in 28.3 and 16.1% participants, respectively. BQ score was independently associated with high BMI ( P < 0.001), Framingham risk >10% ( P < 0.001), and both DAD-10R and -10F score >10% ( P < 0.001 and P = 0.031). PSQI and ISI scores were independently associated with depression and anxiety ( P < 0.001). No association between SDs and specific antiretroviral regimens, nor HIV-related parameters was detected.
CONCLUSIONS
In our cohort of PWH on stable ART, despite the alarmingly higher prevalence, SDs were associated with the same determinants (cardiovascular risk factors and MDs) observed in the general population.
Identifiants
pubmed: 36723511
doi: 10.1097/QAD.0000000000003493
pii: 00002030-202305010-00008
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
925-934Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Zielinski MR, McKenna JT, McCarley RW. Functions and mechanisms of sleep . AIMS Neurosci 2016; 3:67–104.
Alhola P, Polo-Kantola P. Sleep deprivation: impact on cognitive performance . Neuropsychiatr Dis Treat 2007; 3:553–567.
Covassin N, Singh P. Sleep duration and cardiovascular disease risk: epidemiologic and experimental evidence . Sleep Med Clin 2016; 11:81–89.
Smiley A, King D, Bidulescu A. The association between sleep duration and metabolic syndrome: the NHANES 2013/2014 . Nutrients 2019; 11:2582.
Ram S, Seirawan H, Kumar SK, Clark GT. Prevalence and impact of sleep disorders and sleep habits in the United States . Sleep Breath 2010; 14:63–70.
Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? . JAMA 1989; 262:1479–1484.
Quera-Salva MA, Orluc A, Goldenberg F, Guilleminault C. Insomnia and use of hypnotics: study of a French population . Sleep 1991; 14:386–391.
Ohayon MM. Prevalence and comorbidity of sleep disorders in general population . Rev Prat 2007; 57:1521–1528.
Gamaldo CE, Gamaldo A, Creighton J, Salas RE, Selnes OA, David PM, et al. Evaluating sleep and cognition in HIV . J Acquir Immune Defic Syndr 2013; 63:609–616.
Gamaldo CE, Spira AP, Hock RS, Salas RE, McArthur JC, David PM, et al. Sleep, function and HIV: a multimethod assessment . AIDS Behav 2013; 17:2808–2815.
Chaponda M, Aldhouse N, Kroes M, Wild L, Robinson C, Smith A. Systematic review of the prevalence of psychiatric illness and sleep disturbance as co-morbidities of HIV infection in the UK . Int J STD AIDS 2018; 29:704–713.
Milinkovic A, Singh S, Simmons B, Pozniak A, Boffito M, Nwokolo N. Multimodality assessment of sleep outcomes in people living with HIV performed using validated sleep questionnaires . Int J STD AIDS 2020; 31:996–1003.
Patterson F, Connick E, Brewer B, Grandner MA. HIV status and sleep disturbance in college students and relationship with smoking . Sleep Health 2019; 5:395–400.
Duko B, Ayalew M, Ayano G. The prevalence of alcohol use disorders among people living with HIV/AIDS: a systematic review and meta-analysis . Subst Abuse Treat Prev Policy 2019; 14:52.
Stein MD, Friedmann PD. Disturbed sleep and its relationship to alcohol use . Subst Abus 2005; 26:1–13.
Gutierrez J, Tedaldi EM, Armon C, Patel V, Hart R, Buchacz K. Sleep disturbances in HIV-infected patients associated with depression and high risk of obstructive sleep apnea . SAGE Open Med 2019; 7:2050312119842268.
Fekete EM, Williams SL, Skinta MD. Internalised HIV-stigma, loneliness, depressive symptoms and sleep quality in people living with HIV . Psychol Health 2018; 33:398–415.
Bedaso A, Abraham Y, Temesgen A, Mekonnen N. Quality of sleep and associated factors among people living with HIV/AIDS attending ART clinic at Hawassa University comprehensive specialized Hospital, Hawassa, SNNPR, Ethiopia . PLoS One 2020; 15:e0233849.
Chambers LA, Rueda S, Baker DN, Wilson MG, Deutsch R, Raeifar E, et al. Stigma, HIV and health: a qualitative synthesis . BMC Public Health 2015; 15:848.
Zareifopoulos N, Lagadinou M, Karela A, Pouliasi F, Economou I, Tsigkou A, et al. Efavirenz as a psychotropic drug . Eur Rev Med Pharmacol Sci 2020; 24:10729–10735.
Shikuma CM, Kohorn L, Paul R, Chow DC, Kallianpur KJ, Walker M, et al. Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy . HIV Clin Trials 2018; 19:139–147.
Gallego L, Barreiro P, del Rio R, Gonzalez de Requena D, Rodriguez-Albarino A, Gonzalez-Lahoz J, et al. Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz . Clin Infect Dis 2004; 38:430–432.
Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs . CNS Drugs 2014; 28:131–145.
Hoffmann C, Llibre JM. Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors . AIDS Rev 2019; 21:4–10.
Capetti AF, Di Giambenedetto S, Latini A, Sterrantino G, De Benedetto I, Cossu MV, et al. Morning dosing for dolutegravir-related insomnia and sleep disorders . HIV Med 2018; 19:e62–e63.
Elliot ER, Wang X, Singh S, Simmons B, Vera JH, Miller RF, et al. Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition . Clin Infect Dis 2019; 68:87–95.
Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, et al. Psychiatric symptoms in patients receiving dolutegravir . J Acquir Immune Defic Syndr 2017; 74:423–431.
Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, Lopez-Cortes L, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, noninferiority trial . Lancet HIV 2018; 5:e357–e365.
Taibi DM. Sleep disturbances in persons living with HIV . J Assoc Nurses AIDS Care 2013; 24: (1 Suppl): S72–85.
Omonuwa TS, Goforth HW, Preud’homme X, Krystal AD. The pharmacologic management of insomnia in patients with HIV . J Clin Sleep Med 2009; 5:251–262.
Rogers BG, Bainter SA, Smith-Alvarez R, Wohlgemuth WK, Antoni MH, Rodriguez AE, et al. Insomnia, health, and health-related quality of life in an urban clinic sample of people living with HIV/AIDS . Behav Sleep Med 2021; 19:516–532.
Hemar V, Hessamfar M, Neau D, Vareil MO, Rouanes N, Lazaro E, et al. A comprehensive analysis of excess depressive disorder in women and men living with HIV in France compared to the general population . Sci Rep 2022; 12:6364.
Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study . JAMA 2001; 285:1466–1474.
Wong C, Gange SJ, Moore RD, Justice AC, Buchacz K, Abraham AG, et al. Multimorbidity among persons living with human immunodeficiency virus in the United States . Clin Infect Dis 2018; 66:1230–1238.
Polanka BM, Kundu S, So-Armah KA, Freiberg MS, Gupta SK, Zapolski TCB, et al. Insomnia symptoms and biomarkers of monocyte activation, systemic inflammation, and coagulation in HIV: Veterans Aging Cohort Study . PLoS One 2021; 16:e0246073.
Wibbeler T, Reichelt D, Husstedt IW, Evers S. Sleepiness and sleep quality in patients with HIV infection . J Psychosom Res 2012; 72:439–442.
Chen YC, Lin CY, Li CY, Zhang Y, Ko WC, Ko NY. Obstructive sleep apnea among HIV-infected men in the highly active antiretroviral therapy era: a nation-wide longitudinal cohort study in Taiwan, 2000-2011 . Sleep Med 2020; 65:89–95.
Asgari S, Najafi A, Sadeghniiat K, Gholamypour Z, Akbarpour S. The association between body mass index and risk of obstructive sleep apnea among patients with HIV . J Res Med Sci 2021; 26:123.
Alikhani M, Ebrahimi A, Farnia V, Khazaie H, Radmehr F, Mohamadi E, et al. Effects of treatment of sleep disorders on sleep, psychological and cognitive functioning and biomarkers in individuals with HIV/AIDS and under methadone maintenance therapy . J Psychiatr Res 2020; 130:260–272.
Schulz R, Lohmeyer J, Seeger W. Obstructive sleep apnea due to HIV-associated lipodystrophy . Clin Infect Dis 2003; 37:1398–1399.
Chen YC, Chen CC, Strollo PJJr, Li CY, Ko WC, Lin CY, et al. Differences in sleep disorders between hiv-infected persons and matched controls with sleep problems: a matched-cohort study based on laboratory and survey data . J Clin Med 2021; 10:5206.
Patil SP, Brown TT, Jacobson LP, Margolick JB, Laffan A, Johnson-Hill L, et al. Sleep disordered breathing, fatigue, and sleepiness in HIV-infected and -uninfected men . PLoS One 2014; 9:e99258.
Njoh AAMEN, Mbi VO, Mengnjo MK, Nfor LN, Ngarka L, Chokote SE, et al. Likelihood of obstructive sleep apnea in people living with HIV in Cameroon – preliminary findings . Sleep Sci Pract 2017; 1:2925.
Goswami U, Baker JV, Wang Q, Khalil W, Kunisaki KM. Sleep apnea symptoms as a predictor of fatigue in an urban HIV clinic . AIDS Patient Care STDS 2015; 29:591–596.
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale . Sleep 1991; 14:540–545.
Bastien CH, Vallieres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research . Sleep Med 2001; 2:297–307.
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research . Psychiatry Res 1989; 28:193–213.
Backhaus J, Junghanns K, Broocks A, Riemann D, Hohagen F. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia . J Psychosom Res 2002; 53:737–740.
Curcio G, Tempesta D, Scarlata S, Marzano C, Moroni F, Rossini PM, et al. Validity of the Italian version of the Pittsburgh Sleep Quality Index (PSQI) . Neurol Sci 2013; 34:511–519.
Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome . Ann Intern Med 1999; 131:485–491.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus . Arch Neurol 1989; 46:1121–1123.
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7 . Arch Intern Med 2006; 166:1092–1097.
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure . J Gen Intern Med 2001; 16:606–613.
Croston M, Petrak J, Ustianowski A. Use of the wellness thermometer to improve consultations for patients with human immunodeficiency virus . Nurs Stand 2017; 31:46–53.
D’Agostino RBSr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study . Circulation 2008; 117:743–753.
Friis-Moller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study . Eur J Prev Cardiol 2016; 23:214–223.
WHO guidelines on physical activity and sedentary behaviour. 2020. Geneva: World Health Organization. Available at: https://www.who.int/publications/i/item/9789240015128 [Accessed 31 October 2022].
World Health Organization. Health topics /alcohol. Available at: https://www.who.int/health-topics/alcohol [Accessed 31 October 2022].
Beezer J, Al Hatrushi M, Husband A, Kurdi A, Forsyth P. Polypharmacy definition and prevalence in heart failure: a systematic review . Heart Fail Rev 2022; 27:465–492.
Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW. Defining and measuring multimorbidity: a systematic review of systematic reviews . Eur J Public Health 2019; 29:182–189.
Centers for Disease Control and Prevention. How much sleep do i need? Available at: https://www.cdc.gov/sleep/about_sleep/how_much_sleep.html . [Accessed 31 October 2022].
Wu J, Wu H, Lu C, Guo L, Li P. Self-reported sleep disturbances in HIV-infected people: a meta-analysis of prevalence and moderators . Sleep Med 2015; 16:901–907.
Allavena C, Guimard T, Billaud E, de la Tullaye S, Reliquet V, Pineau S, et al. Prevalence and risk factors of sleep disturbances in a large HIV-infected adult population . J Int AIDS Soc 2014; 17: (Suppl 3): 19576.
Shoib S, Malik JA, Masoodi S. Depression as a manifestation of obstructive sleep apnea . J Neurosci Rural Pract 2017; 8:346–351.
St-Onge MP, Grandner MA, Brown D, Conroy MB, Jean-Louis G, Coons M, et al. Sleep duration and quality: impact on lifestyle behaviors and cardiometabolic health: a scientific statement from the American Heart Association . Circulation 2016; 134:e367–e386.
Huang T, Mariani S, Redline S. Sleep irregularity and risk of cardiovascular events: the multi-ethnic study of atherosclerosis . J Am Coll Cardiol 2020; 75:991–999.
Wallace ML, Buysse DJ, Redline S, Stone KL, Ensrud K, Leng Y, et al. Multidimensional sleep and mortality in older adults: a machine-learning comparison with other risk factors . J Gerontol A Biol Sci Med Sci 2019; 74:1903–1909.
Huang T, Redline S. Cross-sectional and prospective associations of actigraphy-assessed sleep regularity with metabolic abnormalities: the multi-ethnic study of atherosclerosis . Diabetes Care 2019; 42:1422–1429.
Frank S, Gonzalez K, Lee-Ang L, Young MC, Tamez M, Mattei J. Diet and sleep physiology: public health and clinical implications . Front Neurol 2017; 8:393.
Kline CE. The bidirectional relationship between exercise and sleep: Implications for exercise adherence and sleep improvement . Am J Lifestyle Med 2014; 8:375–379.
LaGrotte C, Fernandez-Mendoza J, Calhoun SL, Liao D, Bixler EO, Vgontzas AN. The relative association of obstructive sleep apnea, obesity and excessive daytime sleepiness with incident depression: a longitudinal, population-based study . Int J Obes (Lond) 2016; 40:1397–1404.
Dopp JM, Reichmuth KJ, Morgan BJ. Obstructive sleep apnea and hypertension: mechanisms, evaluation, and management . Curr Hypertens Rep 2007; 9:529–534.
Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea . Circulation 1998; 98:772–776.
Brower KJ, Perron BE. Sleep disturbance as a universal risk factor for relapse in addictions to psychoactive substances . Med Hypotheses 2010; 74:928–933.
Brower KJ. Insomnia alcoholism and relapse . Sleep Med Rev 2003; 7:523–539.
Colrain IM, Turlington S, Baker FC. Impact of alcoholism on sleep architecture and EEG power spectra in men and women . Sleep 2009; 32:1341–1352.
Currie SR, Clark S, Rimac S, Malhotra S. Comprehensive assessment of insomnia in recovering alcoholics using daily sleep diaries and ambulatory monitoring . Alcohol Clin Exp Res 2003; 27:1262–1269.
Hornyak M, Haas P, Veit J, Gann H, Riemann D. Magnesium treatment of primary alcohol-dependent patients during subacute withdrawal: an open pilot study with polysomnography . Alcohol Clin Exp Res 2004; 28:1702–1709.
Babson KA, Boden MT, Harris AH, Stickle TR, Bonn-Miller MO. Poor sleep quality as a risk factor for lapse following a cannabis quit attempt . J Subst Abuse Treat 2013; 44:438–443.
Besedovsky L, Lange T, Haack M. The sleep-immune crosstalk in health and disease . Physiol Rev 2019; 99:1325–1380.
Lozupone CA, Li M, Campbell TB, Flores SC, Linderman D, Gebert MJ, et al. Alterations in the gut microbiota associated with HIV-1 infection . Cell Host Microbe 2013; 14:329–339.
Redman KN, Karstaedt AS, Scheuermaier K. Increased CD4 counts, pain and depression are correlates of lower sleep quality in treated HIV positive patients with low baseline CD4 counts . Brain Behav Immun 2018; 69:548–555.